Sign In

Feyi Ayodele

CEO at Cancer IQ, Inc. - we're hiring!

Feyi Ayodele is a prominent figure in the field of cancer prevention and prediction through the utilization of genetic information.

With a strong educational background, Feyi Ayodele has studied at prestigious institutions such as St. Paul's School, University of Chicago Laboratory Schools, and holds an MBA and BSc from the renowned University of Pennsylvania - The Wharton School.

Currently serving as the Chief Executive Officer at Cancer IQ, Inc., Feyi Ayodele has held various key positions in organizations like Rock Health, University of Chicago Hospitals, McKinsey & Company, Actis, Wharton Social Venture Fund, African Capital Alliance, Constant Capital, and Credit Suisse.

Feyi Ayodele's expertise spans from project management to investment, social ventures, and clinical cancer genetics, making a significant impact on the healthcare sector.

Known for their dedication to using genetic data to tailor cancer prevention strategies for diverse populations, Feyi Ayodele's leadership at Cancer IQ, Inc., showcases a commitment to improving healthcare outcomes at scale.

Highlights

Jun 20 · linkedin

On Juneteenth, I took a moment to commemorate a day that has made so much possible for me. I unplugged. I celebrated with friends. I enjoyed the perfect summer weather by the lake in Chicago. I forgot to post.

Although we have been free from the burden of slavery for nearly 200 years, I am deeply grateful for the choices people continue to make that shape my journey. I am thankful for my employees who choose to work for a Black woman with a big vision. I appreciate my investors who chose to invest in me, despite less than 1% of venture capital going to people who look like me. I am grateful for my customers who choose to do business with me and uphold their diversity supplier goals. And I am especially thankful for the hundreds of thousands of patients who benefit from our technology, which would not be possible without the end of slavery.

Juneteenth is also a day for learning and reflection, and I want to share what drives me at CancerIQ .

Despite many advances in oncology, too many people of color continue to die from cancer. African American women are 40% more likely to die of breast cancer than white women, and we are often diagnosed with more aggressive, harder-to-treat diseases at younger ages. The breast cancer death rate for Black women under 50 is twice that of white women. Simply put, when we’re diagnosed with cancer, we don’t win.

It’s time for a different approach. Equitable cancer care begins when we recognize that every patient shouldn’t be treated the same because every patient’s risk isn’t the same. Full stop.

That’s why I’m proud to say, in the spirit of Juneteenth, that we’re doing something dramatically different at CancerIQ. We are bringing cancer risk assessment out of the clinic to meet patients where they are and to maximize the reach of the genetics workforce. We are producing culturally tailored patient education to promote positive health behaviors. We are sensitive to the fact that “who communicates matters,” working with community health workers, and providing navigation services to populations who really can’t afford to get cancer.

Stay tuned for more updates on the progress we're making to end cancer as we know it, for everyone.

Jun 23 · linkedin

Last week we celebrated CancerIQ’s 10th anniversary, and I couldn't be more proud of how much we’ve grown. Most startups never make it to 10 years, and we did it with flying colors (and a lot of grit): our platform is being used in over 200 clinical locations nationwide to turn cancer risk assessment and genetic testing into actionable, evidence-based care plans that save lives.

We have a lot of things to thank for this success - 2013 was the year the Supreme Court ruled against patenting human genes and an influx of labs entered the market. It was also the year I decided to defer McKinsey & Company to work with Olufunmilayo (Funmi) Olopade at the University of Chicago Medicine Comprehensive Cancer Center, and the year my co-founder Haibo Lu Lu, started business school at The University of Chicago Booth School of Business. Our worlds collided and the wind was behind us.

Over the last 10 years, our success has been testament to our steadfast belief that we can get ahead of cancer. Today, we are the only platform independent from genetic testing labs and continue to be a pioneer in the cancer prevention and early detection space.

The time for bigger and bolder is now, and we are humbled by the potential impact CancerIQ can have on patients and their families in the next decade. Thanks to the amazing CancerIQ-ers that have gotten us to this place, to the investors and partners who believe I'm us, and here’s to the next 10 years!

And for the full play-by-play of all our big milestones - check out our latest blog post: https://lnkd.in/gR9uBGpU

Feyi Ayodele
Add to my network

Location

Chicago, Illinois